Draft:MSX-3
 | Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by 76.174.0.57 (talk | contribs) 0 seconds ago. (Update) |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H23N4O7P |
| Molar mass | 474.410 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MSX-3 is a selective adenosine A2A receptor antagonist.[1][2] Similarly to MSX-4, it is a water-soluble phosphate ester prodrug of MSX-2.[2][3] MSX-3 shows pro-motivational effects in animals.[1][4] Specifically, although it showed no effect on its own, the drug reverses the effort-related deficits induced by the dopamine depleting agent tetrabenazine (TBZ), the dopamine D2 receptor antagonists haloperidol and eticlopride, and the proinflammatory cytokines interleukin-6 and interleukin-1β.[1][4][5][6][7][8] Conversely, it only mildly attenuates the motivational deficits induced by the dopamine D1 receptor antagonist ecopipam (SCH-39166).[5][9]
References
[edit]- ^ a b c Salamone JD, Correa M, Ferrigno S, Yang JH, Rotolo RA, Presby RE (October 2018). "The Psychopharmacology of Effort-Related Decision Making: Dopamine, Adenosine, and Insights into the Neurochemistry of Motivation". Pharmacol Rev. 70 (4): 747–762. doi:10.1124/pr.117.015107. PMC 6169368. PMID 30209181.
- ^ a b Müller CE (November 2009). "Prodrug approaches for enhancing the bioavailability of drugs with low solubility". Chem Biodivers. 6 (11): 2071–2083. doi:10.1002/cbdv.200900114. PMID 19937841.
- ^ Hauber W, Nagel J, Sauer R, Müller CE (June 1998). "Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen". Neuroreport. 9 (8): 1803–1806. doi:10.1097/00001756-199806010-00024. PMID 9665604.
- ^ a b López-Cruz L, Salamone JD, Correa M (2018). "Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression". Front Pharmacol. 9: 526. doi:10.3389/fphar.2018.00526. PMC 5992708. PMID 29910727.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b Salamone, John D; Correa, Merce; Farrar, Andrew M; Nunes, Eric J; Collins, Lyndsey E (5 May 2010). "Role of dopamine–adenosine interactions in the brain circuitry regulating effort-related decision making: insights into pathological aspects of motivation". Future Neurology. 5 (3): 377–392. doi:10.2217/fnl.10.19. ISSN 1479-6708.
- ^ Mott AM, Nunes EJ, Collins LE, Port RG, Sink KS, Hockemeyer J, Müller CE, Salamone JD (May 2009). "The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure". Psychopharmacology (Berl). 204 (1): 103–112. doi:10.1007/s00213-008-1441-z. PMC 2875244. PMID 19132351.
- ^ Nunes EJ, Randall PA, Estrada A, Epling B, Hart EE, Lee CA, Baqi Y, Müller CE, Correa M, Salamone JD (February 2014). "Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task". Psychopharmacology (Berl). 231 (4): 727–736. doi:10.1007/s00213-013-3285-4. PMC 4468782. PMID 24136220.
- ^ Yohn SE, Arif Y, Haley A, Tripodi G, Baqi Y, Müller CE, Miguel NS, Correa M, Salamone JD (October 2016). "Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization". Psychopharmacology (Berl). 233 (19–20): 3575–3586. doi:10.1007/s00213-016-4392-9. PMID 27497935.
- ^ Worden LT, Shahriari M, Farrar AM, Sink KS, Hockemeyer J, Müller CE, Salamone JD (April 2009). "The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists". Psychopharmacology (Berl). 203 (3): 489–499. doi:10.1007/s00213-008-1396-0. PMC 2875246. PMID 19048234.